---
title: "For three consecutive days, it has \"sucked in\" over 150 million yuan, with the Innovative Drugs ETF (159992) having a trading volume exceeding 73 million yuan during the session, ranking first among the same category. Institutions: The investment risk-reward ratio in the innovative drug sector is gradually improving"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279190416.md"
description: "On March 16, the three major A-share indices collectively fell, with the CSI Innovative Drugs Industry Index down 0.31%. The Innovative Drugs ETF (159992) had a trading volume exceeding 73 million yuan, with a net inflow of funds totaling 152 million yuan over three consecutive days. This ETF closely tracks the CSI Innovative Drugs Industry Index, with the latest circulating scale at 14.592 billion yuan. Dongguan Securities pointed out that the investment risk-reward ratio in the innovative drug sector is gradually improving and suggested paying attention to investment opportunities in the innovative drug industry chain"
datetime: "2026-03-16T02:09:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279190416.md)
  - [en](https://longbridge.com/en/news/279190416.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279190416.md)
---

# For three consecutive days, it has "sucked in" over 150 million yuan, with the Innovative Drugs ETF (159992) having a trading volume exceeding 73 million yuan during the session, ranking first among the same category. Institutions: The investment risk-reward ratio in the innovative drug sector is gradually improving

On March 16, the three major indices of A-shares collectively fell, with the CSI Innovative Drugs Industry Index down 0.31% as of the time of publication. Among the constituent stocks of this index, Xinlitai rose over 3%, while Haike, Watson Bio, Tonghua Golden Horse, and others rose over 1%.

In related ETFs, the **Innovative Drugs ETF (159992)** was down 0.25% as of the time of publication, with a trading volume exceeding 73 million yuan, ranking first among the same underlying assets.

In terms of capital flow, Wind Financial Terminal data shows that the **Innovative Drugs ETF (159992)** has seen net inflows for three consecutive trading days, with a cumulative net inflow of 152 million yuan; the latest circulating shares of this ETF are 18.376 billion shares, with a latest circulating scale of 14.592 billion yuan.

The Innovative Drugs ETF (159992) closely tracks the CSI Innovative Drugs Industry Index, which selects no more than 50 of the most representative listed company securities involved in innovative drug research and development from the securities of listed companies in the innovative drug industry to reflect the overall performance of the securities of listed companies in this sector.

**Dongguan Securities** stated that the pharmaceutical and biotechnology sector has continued to adjust recently, with most sub-sectors weakening, while some medical consumables sub-sectors at low levels have shown performance. As the innovative drug sector continues to adjust, **the investment risk-reward ratio in the sector is gradually increasing**, and it is recommended to look for investment opportunities in the innovative drug industry chain.

### Related Stocks

- [516080.CN](https://longbridge.com/en/quote/516080.CN.md)
- [159835.CN](https://longbridge.com/en/quote/159835.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [560900.CN](https://longbridge.com/en/quote/560900.CN.md)

## Related News & Research

- [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md)
- [Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs](https://longbridge.com/en/news/287197958.md)
- [1 Rapidly Deteriorating ETF Screams That ‘Shop ‘Til You Drop’ Americans Have All But Keeled Over](https://longbridge.com/en/news/286429552.md)
- [Worried About a Market Crash? 3 Vanguard ETFs Built to Survive](https://longbridge.com/en/news/286880525.md)
- [New Core Equity ETF Drops As Low-Cost Active Funds Become Wall Street's New Obsession](https://longbridge.com/en/news/287253853.md)